Additional Proxy Soliciting Materials (definitive) (defa14a)
April 25 2017 - 4:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section
14(a) of the
Securities Exchange Act of 1934 (Amendment No. )
☑
|
Filed by the Registrant
|
☐
|
Filed by a Party other
than the Registrant
|
|
CHECK THE APPROPRIATE BOX:
|
☐
|
|
Preliminary Proxy Statement
|
☐
|
|
Confidential, For Use of the Commission Only
(as permitted by Rule 14a-6(e)(2))
|
☐
|
|
Definitive Proxy Statement
|
☑
|
|
Definitive Additional Materials
|
☐
|
|
Soliciting Material Under § 240.14a-12
|
BioMarin Pharmaceutical Inc.
(Name of Registrant as Specified In Its
Charter)
(Name of Person(s) Filing Proxy
Statement, if Other Than the Registrant)
PAYMENT OF FILING FEE (CHECK THE APPROPRIATE
BOX):
|
☑
|
|
No fee
required.
|
☐
|
|
Fee computed on table below per Exchange Act Rules
14a-6(i)(1) and 0-11.
|
|
|
|
1)
Title of each class of securities to which transaction
applies:
|
|
|
|
2)
Aggregate number of securities to which transaction applies:
|
|
|
|
3)
Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
|
|
|
|
4)
Proposed maximum aggregate value of transaction:
|
|
|
|
5) Total fee paid:
|
☐
|
|
Fee paid previously with
preliminary materials:
|
☐
|
|
Check box if any part of the fee is
offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing
for which the offsetting fee was paid previously. Identify the previous
filing by registration statement number, or the form or schedule and the
date of its filing.
|
|
|
|
1)
Amount previously paid:
|
|
|
|
2)
Form, Schedule or Registration Statement No.:
|
|
|
|
3)
Filing Party:
|
|
|
|
4) Date
Filed:
|
*** Exercise
Your
Right
to Vote ***
Important Notice Regarding the Availability of Proxy Materials for
the
Stockholder Meeting to Be Held on June 06, 2017
BIOMARIN
PHARMACEUTICAL INC.
BIOMARIN PHARMACEUTICAL INC.
105
DIGITAL DRIVE
NOVATO, CA
94949
ATTN: G. ERIC DAVIS, EVP &
GENERAL COUNSEL
Meeting Information
|
|
Meeting
Type:
Annual Meeting
|
|
|
For
holders as of:
April 10, 2017
|
|
|
Date:
June 06, 2017
Time:
9:00 AM PDT
|
|
|
Location:
|
BioMarin Pharmaceutical Inc.
|
|
|
|
Seminar
Room
|
|
|
|
770 Lindaro
Street
|
|
|
|
San Rafael, CA
94901
|
|
|
|
For Directions, visit www.biomarin.com
- "Contact us"
|
|
You are receiving this communication
because you hold shares in the above named company.
This is not a ballot. You cannot use
this notice to vote these shares. This communication presents only an overview
of the more complete proxy materials that are available to you on the Internet.
You may view the proxy materials online at
www.proxyvote.com
or easily request a
paper copy (see reverse side).
We encourage you to access and review
all of the important information contained in the proxy materials before
voting.
See the reverse side of this notice
to obtain proxy materials and voting
instructions.
|
Before You Vote
How to Access the Proxy Materials
|
Proxy Materials Available
to VIEW or
RECEIVE:
|
|
|
1. Notice & Proxy
Statement 2. Form
10-K 3. CEO Stockholder
Letter
|
|
|
How to View
Online:
|
|
|
|
|
Have the information that is printed in
the box marked by the arrow →
XXXX XXXX XXXX XXXX
(located on the following page) and visit:
www.proxyvote.com.
|
|
|
How to
Request and Receive a PAPER or E-MAIL Copy:
|
|
|
If you want to receive a paper or e-mail
copy of these documents, you must request one. There is NO charge for
requesting a copy. Please choose one of the following methods to make your
request:
|
|
|
|
1)
BY
INTERNET
:
|
www.proxyvote.com
|
|
|
|
2)
BY
TELEPHONE:
|
1-800-579-1639
|
|
|
|
3)
BY E-MAIL*
:
|
sendmaterial@proxyvote.com
|
|
|
* If requesting
materials by e-mail, please send a blank e-mail with the information that
is printed in the box marked by the arrow →
XXXX XXXX XXXX XXXX
(located on the following page) in the subject line.
Requests, instructions and other inquiries sent to this e-mail
address will NOT be forwarded to your investment advisor. Please make the
request as instructed above on or before May 23, 2017 to facilitate timely
delivery.
|
|
How To Vote
Please Choose One of the Following Voting
Methods
|
Vote In Person:
Many stockholder meetings have attendance requirements including, but not limited to, the possession
of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special
requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.
|
|
|
Vote By Internet:
To vote now by Internet, go to
www.proxyvote.com.
Have the information that is printed in the box marked by the arrow
→
XXXX XXXX XXXX XXXX
available and follow the instructions.
|
|
|
Vote By Mail:
You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.
|
|
|
|
|
Voting
items
|
The
Board of Directors recommends you vote
FOR the
following:
|
1.
|
|
Election of
Directors
|
|
|
|
|
|
Nominees
|
01
|
Jean-Jacques
Bienaimé
|
|
02
|
Willard
Dere
|
|
03
|
Michael
Grey
|
|
04
|
Elaine J.
Heron
|
|
05
|
V. Bryan
Lawlis
|
06
|
Alan J.
Lewis
|
|
07
|
Richard A.
Meier
|
|
08
|
David
Pyott
|
|
09
|
Dennis J.
Slamon
|
|
|
|
The Board of Directors recommends you
vote FOR the following proposal:
2
|
To ratify the selection of KPMG LLP as the independent
registered public accounting firm for BioMarin for the fiscal year ending
December 31, 2017.
|
The Board of Directors recommends
you vote 1 YEAR on the following proposal:
3
|
To approve, on an advisory basis,
the frequency of the stockholders' approval, on an advisory basis, of the
compensation of the Company's Named Executive Officers as disclosed in the
Proxy Statement.
|
The Board of Directors recommends
you vote FOR proposals 4, 5 and 6.
4
|
To approve,
on an advisory basis, the compensation of the Company's Named Executive
Officers as disclosed in the Proxy Statement.
|
|
|
5
|
To approve
the 2017 Equity Incentive Plan.
|
6
|
To approve amendments to BioMarin's Amended and Restated
Certificate of Incorporation, as amended, to (i) increase the total number
of authorized shares of common stock from 250,000,000 shares to
500,000,000 shares, and (ii) make certain minor administrative
changes.
|
NOTE:
Your proxy holder will also vote on
any other business properly brought before the Annual Meeting.
|
|
|
|
|
|
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Apr 2024 to May 2024
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From May 2023 to May 2024